Clinical research helps elucidate the role of tumor necrosis factor-α in the pathogenesis of T1-mediated immune disorders: Use of targeted immunotherapeutics as pathogenic probes

Lupus

Volumn 12, Issue 3, 2003, Pages 190-194

  Gottlieb, A B ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Immunobiologics; Psoriasis; T cell activation; TNF

Indexed keywords

ALEFACEPT; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; IMMUNOBIOLOGY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; JOINT DESTRUCTION; LONG TERM CARE; MOLECULAR PROBE; PATHOGENESIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REMISSION; SKIN MANIFESTATION; SUICIDE; SYMPTOM; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037269890     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu354xx     Document Type: Article

References (46)

1. Bos JD, VanJoost T, Powles AV, Meinardi MMHM, Fry L. Use of cyclosporin in psoriasis. Lancet 1989; 23: 1500-1505.
2. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. New Engl J Med 1991; 324: 277-284.
3. Gottlieb AB, Krueger JG, Khandke L et al. Cyclosporine A treatment decreases immune activation in psoriatic plaques without decreasing keratinocyte regenerative maturation (growth activation). J Invest Detmatol 1991; 96: 570.
4. Khandke L, Ashinoff R, Krane JF et al. Cycloporine in psoriasis treatment: Inhibition of keratinocyte cell-cycle progression in G1 independent of effects on transforming growth factor-alpha/epidermal growth factor receptor pathways. Arch. Dermatol 1991; 127: 1172-1179.
5. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
6. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 1995; 146: 580-588.
7. Gottlieb AB. Psoriasis: Immunopathology and Immunomodulation. Derm Clin 2001; 19: 649-657.
8. Trepicchio W, Ozawa M, Walters IB et al. IL-11 is an immune-modulatory cytokine which downregulates IL-12, Type 1 cytokines, and multiple inflammation-associated genes in patients with psoriasis. J Invest Dermatol 1999; 112: 598.
9. Austin L, Ozawa M, Kikuchi T, Krueger G. Intracellular TNF-alpha, IFN-gamma, and IL-2 identify TC1 and TH1 effector populations in psoriasis vulgaris plaque lymphocytes: single-cell analysis by flow cytometry. J Invest Dermatol 1998; 110: 649.
10. Grossman RM, Krueger J, Yourish D et al. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989; 86: 6367-6371.
11. Sticherling M, Bornscheuer E, Schroder JM, Christophers E. Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol 1991; 96: 26-30.
12. Livden JK, Nilsen R, Bjerke JR, Matre R. In situ localization of interferons in psoriatic lesions. Arch Dermatol Res 1989; 281: 392-397.
13. Choy EHS, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. New Engl J Med 2001; 344: 907-916.
14. Norris DA. Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol 1990; 95: 111S-120S.
15. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20: 617-629.
16. Sato N, Nariuchi H, Tsuruoka N et al. Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol 1990; 95: 85S-89S.
17. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-884.
18. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal anti-body cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-259.
19. tenHove T, vanMontfrans C, Peppelenbosch MP. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002 50: 206-211.
20. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-1847.
21. Maini R, St.Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor-alpha monoclonal antibody) versus placebo in theumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932-1939.
22. Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830.
23. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New Engl J Med 1999; 340: 1398-1401.
24. Targan SR, Hanauer SB, VanDeventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. New Engl J Med 1997; 337: 1029-1035.
25. VanOosten BW, Barkhof F, Truyen L et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with monoclonal anti-tumor necrosis factor antibody CA2. Neurology 1996; 47: 1531-1534.
26. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor monoclonal antibody (Infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003; 48: 68-75.
27. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
28. Frederiksson T, Pettersson U. Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
29. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial. Arthritis Rheum 2001; 44: S90.
30. Gottlieb AB, Matheson RT, Lowe NJ, Zitnik RJ. Efficacy of Enbrel in patients with psoriasis. J Invest Dermatol 2002; 11: 234.
31. Amason BGW, Lenercept MSSG. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457-465.
32. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34: 365-367.
33. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmac Ther 1999; 13: 16-22.
34. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with inflximimab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
35. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. New Engl J Med 2002; 346: 1349-1356.
36. Braughman RPI, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 118: 70-74.
37. Botros N, Pickover L, Das KM. Image of the month. Gastroenterology 2000; 118: 654.
38. Cambell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13: 191-192.
39. Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with infiximab in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol 2000; 12: 582-587.
40. De Clercq E. Perspectives for the chemotherapy of AIDS. Anticancer Res 1987; 7: 1023-1038.
41. Fabrizio C, Niccoli L, Salvarani C, Padula A, Olivieri. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 2001; 44: 2933-2935.
42. Martinez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflammatory Bowel Dis 2001; 7: 323-326.
43. Schothorst AA, Evers LM, Noz KC, Filon R, van Zeeland AA. Pyrimidine dimer induction and repair in cultured human skin keratinocytes or melanocytes after irradiation with monochromatic ultraviolet radiation. J Invest Dermatol 1991; 96: 916-920.
44. Smith JR, Levinson RD, Holland GN et al. Differential effiacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001; 45: 252-257.
45. Steinfeld S, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study Arthritis Rheum 2001; 44: 2371-2375.
46. Tan JH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn Disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137: 930-933.